Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $54.33 Consensus Target Price from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received an average recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $54.33.

Several analysts have recently weighed in on DNTH shares. TD Cowen began coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim reiterated a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $15.60 on Friday. The firm has a market cap of $501.15 million, a P/E ratio of -6.24 and a beta of 1.62. Dianthus Therapeutics has a 1 year low of $13.37 and a 1 year high of $32.27. The stock has a 50-day simple moving average of $20.76 and a 200-day simple moving average of $23.45.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at about $26,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $35,000. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth approximately $59,000. Finally, GAMMA Investing LLC boosted its position in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after purchasing an additional 3,758 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.